Regulation of the HIF-1α stability by histone deacetylases

SE-HEE KIM[1], JOO-WON JEONG[2], JEONG AE PARK[1], JI-WON LEE[1],
JI HAE SEO[1], BO-KYUNG JUNG[1], MOON-KYOUNG BAE[3] and KYU-WON KIM[1]

[1]NeuroVascular Coordination Research Center, Research Institute of Pharmaceutical Sciences,
College of Pharmacy, Seoul National University; [2]Department of Anatomy, MRC for ROS, School of Medicine,
Kyung Hee University, Seoul; [3]College of Dentistry, Pusan National University, Busan, Korea

Abstract. Histone deacetylase inhibitors (HDACIs) are currently in clinical trials partly due to their potent anti-angiogenic effects. However, the detailed mechanism of their action is unclear. Here, we observed that several HDACIs (TSA, SB, Apicidin, and VPA) dramatically decreased HIF-1α protein level and transcriptional activity of HIF-1 in human and mouse tumor cell lines. Furthermore, class I HDACs, HDAC1 and 3 enhanced HIF-1α stability and HIF-1 trans-activation function in hypoxic conditions. In addition, immunoprecipitation and *in vitro* binding assays revealed that HDAC1 and 3 directly bind to the oxygen-dependent degradation domain of HIF-1α. Collectively, these results suggest that HDAC1 and 3 are considered as a positive regulator of HIF-1α stability via direct interaction and may play an important role in HIF-1-induced tumor angiogenesis.

Introduction

HDACs are enzymatic components of multi-protein complexes that are recruited by transcription factors to specific DNA regulatory sequences. They remove acetyl residues from nucleosomal histones and other substrates leading to chromatin condensation and gene repression (1-5). HDACs are divided into three classes: class I HDACs (HDACs 1-3, and 8) are similar to the yeast RPD3 protein and mainly localize to the nucleus (6-8); class II HDACs (HDACs 4-7, 9 and 10) are homologous to the yeast HDA1 protein and are detected in both nucleus and cytoplasm (9-17); and class III HDACs form a structurally distinct class of NAD-dependent enzymes that are similar to the yeast SIR2 proteins (18,19). Major functions of HDACs are to control gene expression, transport ubiquitinated protein aggregates, and deacetylate proteins (20-22).

Global suppression of HDAC activity by chemical inhibitors generally raises cell cycle arrest and may affect cell proliferation and differentiation (23,24). Specific HDACIs have been used to explain HDAC function and suggested as a therapy for some types of cancers (25). Consequently, they have been shown to have the potent anti-tumor activity in human xenograft animal models and are being actively tested in clinical trials.

HIF-1 is a key regulator of many biological processes, including angiogenesis, energy metabolism, and cell survival (26,27). HIF-1 is composed of two subunits: the hypoxia-regulated α subunit, HIF-1α, and the oxygen-insensitive HIF-1ß subunit (28). Under normoxic conditions, the HIF-1α subunit is rapidly degraded via the ubiquitin-proteasome pathway triggered by oxygen-dependent hydroxylation of proline residues in HIF-1α (29,30). Under hypoxic conditions, this oxygen dependent-degradation system is repressed. HIF-1α is able to form a heterodimer with HIF-1ß, bind to hypoxia responsive elements (HREs) in oxygen-regulated genes and activate transcription (31,32).

In the present study, we confirmed that HDACIs significantly decrease HIF-1α protein level and transcriptional activity of HIF-1 in tumor cell lines. Moreover, HDAC1 and 3 directly interact with the ODD domain of HIF-1α, resulting in the increase of HIF-1α stability and HIF-1 transactivation function under hypoxia. Therefore, our results suggest that HDAC1 and 3 have the potential to upregulate HIF-1α stability in hypoxic conditions.

Materials and methods

Reagents and antibodies. Trichostatin A (TSA), sodium butyrate (SB), and valproic acid (VPA) were purchased from Sigma (St. Louis, MO), and apicidin from Calbiochem (Darmstadt, Germany).

Anti-HIF-1α antibodies were purchased from BD Pharmingen (San Diego, CA), Novus Biologicals (Littleton, CO), and Cayman Chemical (Ann Arbor, MI). Flag and GFP antibodies were purchased from Sigma and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.

Plasmids. For luciferase assay, pBOS-hHIF-1α, pBOS-hHIF-1ß, and pSV40pro-EpoHRE-Luc vectors were kindly provided

Figure 1. HDAC inhibitors downregulate HIF-1α stability and HIF-1 transcriptional activity. (A) HeLa or B16F10 cells under normoxia (21% O_2) or hypoxia (1% O_2) for 16 h with treatment of TSA (1 μM), sodium butyrate (SB) (2 mM), apicidin (1 μM), and valproic acid (VPA) (1 mM) were isolated. Protein extracts (30 μg) were examined by SDS-PAGE and analyzed by Western blotting with HIF-1α-specific antibody. α-tubulin served as a loading control. RT-PCR analysis was performed for HIF-1α and ß-actin with total RNA isolated from HeLa and B16F10 cells cultured under normoxia or hypoxia treated with TSA (1 μM), SB (2 mM), apicidin (1 μM), and VPA (1 mM) for 16 h. ß-actin served as a loading control. (B) 293T cells were cotransfected with pSV40pro-EpoHRE-Luc (1 μg), pBOS-hHIF-1α (0.1 μg), pBOS-hHIF-1ß (0.1 μg). Transfected cells were treated under normoxia or hypoxia with TSA (1 μM), SB (2 mM), and apicidin (1 μM) for 16 h. The mean and standard deviation based on three independent transfections are shown.

by Dr Y. Fujii-Kuriyama (Tohoku University, Japan) (33). Mammalian expression vectors, pcDNA3-HDAC1 and pcDNA3-HDAC3 were obtained from Dr W.M. Yang (National ChungHsing University, Taiwan). GFP-HIF-1α expression vector was prepared as previously described (34).

Cell culture and hypoxic condition. 293T, HeLa, and B16F10 cells were maintained in Dulbecco's modified Eagle's

medium (DMEM) (Gibco, Grant Island, NY) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% anti-biotics (Gibco). For hypoxic conditions, cells were incubated at a 5% CO_2 level with 1% O_2 balanced with N_2 in a hypoxic chamber (Forma Scientific, Marietta, OH).

Immunoprecipitation and Western blotting. Transfected cells were lysed in whole cell extract buffer (10 mM HEPES at pH 7.9, 400 mM NaCl, 0.1 mM EDTA, 5% glycerol, 1 mM DTT, protease inhibitors). Anti-Flag antibody (1μg) was added to the lysate, followed by Protein-A agarose (Upstate, Lake Placid, NY) in TEG reaction buffer (20 mM Tris-HCl at pH 7.4, 1 mM EDTA, 10% glycerol, 1 mM DTT, 150 mM NaCl), and the mixture was stirred overnight at 4°C. The immunoprecipitates were washed in TEG washing buffer (TEG reaction buffer containing 0.1% Triton X-100), subjected to SDS-PAGE and transferred onto a nitrocellulose membrane (Amersham Pharmacia Biotech., Buckinghamshire, UK). The membrane was probed with primary antibodies followed by a secondary antibody conjugated with horseradish peroxidase and detected by the ECL plus system (Amersham Bioscience).

In vitro binding assay. Purified ODD protein and immuno-precipitated Flag-HDAC1/3 were mixed alone or together, and Flag-HDAC1/3 was immunoprecipitated with anti-Flag antibody in TEG reaction buffer. The immunoprecipitates were washed by TEG washing buffer three times and were subjected to SDS-PAGE and transferred onto nitro-cellulose membrane (Amersham Bioscience). Immunoblot analysis was carried out with anti-HIF-1α antibody.

Transient transfection and luciferase assays. Five micrograms of plasmids were transfected to 293T cells, with proper recombinations of effector plasmids using calcium phosphate-mediated methods (35). The luciferase and ß-galactosidase enzyme assays were performed as described (34). For overexpressing of HIF-1α or HDAC1/3 expression vectors, subconfluent 293T cells, in 60-mm or 100-mm dishes were transiently transfected with 5-10 μg empty, HIF-1α or HDAC1/3 plasmids using calcium phosphate-mediated methods. In HeLa and B16F10 cells, transient transfection was performed using Lipofectamine plus reagent (Invitrogen, Carlsbad, CA).

RT-PCR analysis. Total RNA was extracted using an RNA extraction kit (Invitrogen). Complementary DNA was synthesized from 4 μg total RNA using an oligo-dT primer. Primers used for PCR were hHIF-1α forward: 5' GGATCC TTAACTTTGCTGGCC 3' and reverse: 5' CCCGGGA GTCTGCTGGAATA 3'; mHIF-1α forward: 5' AGGTGAC TGTGCACCTA 3' and reverse: 5' GCTGTGAATGTG CTGTGA 3'; ß-actin forward: 5' GACTACCTCATGA AGATC 3' and reverse: 5' GATCCACATCTGCTGGAA 3'. Thirty cycles of PCR were carried out to amplify HIF-1α and ß-actin, and signals were detected by autoradiography.

Results

*HDAC inhibitors downregulate HIF-1α stability and transcriptional activity of HIF-1*. We tested the effect of

Figure 2. HDAC1 and 3 increase HIF-1α stability and transcriptional activity of HIF-1 under hypoxia. (A) HeLa or B16F10 cells were transfected with Flag-HDAC1/3 and incubated in hypoxia for 4, 16, or 24 h. Total cell extracts were analyzed by Western blotting with anti-HIF-1α, anti-Flag, and anti-α-tubulin antibodies, respectively. (B) 293T cells were cotransfected with pSV40pro-EpoHRE-Luc (1 μg), pBOS-hHIF-1α (0.1 μg), pBOS-hHIF-1ß (0.1 μg) and 2 μg of pcDNA-HDAC1 or pcDNA-HDAC3 or pcDNA alone. Transfected cells were incubated for 24 h at normoxia and then incubated at normoxia or hypoxia for an additional 16 h. The mean and standard deviation based on three independent transfections are shown.

Figure 3. HDAC1 and 3 interact with HIF-1α *in vivo* and *in vitro*. (A) 293T cells were cotransfected with expression vectors for GFP-HIF-1α and/or pcDNA-Flag-HDAC1/3 or pcDNA alone. After transfection for 24 h, the cell extracts were prepared. Total cell lysates were immunoprecipitated with anti-Flag antibody. The presence of GFP-HIF-1α in the immunoprecipitants was examined using anti-GFP antibody. Immunoprecipitated materials and total cell extracts were analyzed by Western blotting with anti-Flag, anti-GFP, and anti-α-tubulin antibodies, respectively. (B) Immunoprecipitated Flag-HDAC1 and 3 were incubated in the absence or presence of recombinant ODD. After washing the mixture, the bound proteins were separated by SDS-PAGE and subjected to Western blot analysis for HIF-1α. IP, immunoprecipitation.

HDAC activity on HIF-1α expression in hypoxia-exposed cells using several HDACIs (TSA, SB, apicidin, and VPA). As shown in Fig. 1A, HDACIs dramatically decreased the amount of endogenous HIF-1α that was induced by hypoxia, while the inhibitory effect was not observed in the levels of HIF-1α mRNA transcripts in the human HeLa cervical cancer cell line. A similar result was obtained in the murine B16F10 melanoma cancer cell line. To further examine whether HDACIs affected the transactivation of HIF-1, we performed a luciferase reporter system, pSV40promoter-EpoHRE-Luc. Upon transient transfection of HIF-1α/HIF-1ß and EpoHRE-Luc vectors into 293T cells, the reporter activity was markedly inhibited by HDACIs under both normoxic and hypoxic conditions (Fig. 1B). These results suggested that HDACIs negatively regulate both HIF-1α protein level and HIF-1-mediated transcriptional activation. From the above

results, we hypothesized that HDAC activity is closely associated with the stability of HIF-1α.

HDAC1 and 3 upregulate HIF-1α stability and transcriptional activity of HIF-1 in hypoxic conditions. A recent study reported that HDAC1 and HIF-1α were efficiently co-precipitated in human breast cancer cell line MCF-7, indicating that these proteins are capable of forming a complex *in vivo* under hypoxic conditions (36). From these observations, we tested whether class I HDACs, HDAC1 and 3 are involved in the regulation of HIF-1α protein in hypoxic conditions. Therefore, we transfected HDAC1/3 into HeLa or B16F10 cells and then exposed cells to hypoxia for 4, 16, or 24 h. As shown in Fig. 2A, overexpressed HDAC1 and 3 increased the endogenous HIF-1α protein level compared with hypoxia alone in both cell lines. In addition, to examine whether HDAC1 and 3 affected on HIF-1 transcriptional activity, we used a luciferase reporter system, pSV40promoter-EpoHRE-Luc reporter. Ectopic expression of HDAC1 and 3 enhanced the transcriptional activity of HIF-1 compared with hypoxia-stimulated activity in the absence of exogenous HDAC1 and 3 (Fig. 2B). Therefore, this finding indicated that HDAC1 and 3 have the potential to increase HIF-1α stability and HIF-1 transactivation function under hypoxia.

HDAC1 and 3 interact with HIF-1α in vivo and in vitro. To examine the association between HIF-1α and HDAC1/3, we

cotransfected 293T cells with GFP-HIF-1α and Flag-HDAC1/3. When Flag-HDAC1 and 3 proteins were immunoprecipitated from transfected cell extracts using the anti-Flag antibody, GFP-HIF-1α was coimmunoprecipitated (Fig. 3A). Since HDAC1 and 3 regulate the stability of HIF-1α (Fig. 2A), it is plausible that HDAC1 and 3 bind to the ODD domain of HIF-1α. To test this possibility, we performed *in vitro* binding assay using purified recombinant ODD protein and immuno-precipitated Flag-HDAC1 and 3. As shown in Fig. 3B, ODD protein was pulled down with HDAC1 or 3 (Fig. 3B). These results strongly suggested that HDAC1 and 3 directly associate with the ODD region of HIF-1α.

Discussion

HDACIs are considered to be anticancer drugs because of their potential to induce differentiation or apoptosis preferentially in cancer cells (37-39). Based on their persuasive proapoptotic and anti-angiogenic effects, deacetylase inhibitors are tested as potentially essential new chemotherapeutic agents for the remedy of solid tumors (40). Therefore, our results that HDACIs showed suppression of HIF-1α stability appear to play a key role in their anti-angiogenic effects (Fig. 1A) (41-43). In addition, the finding that HIF-1α expression is decreased by TSA suggests the involvement of class I and class II HDACs in the regulation of HIF-1α stability, because most class I/II HDACs are significantly inhibited by TSA, whereas class III HDACs are resistant to TSA. Here, we found that among class I HDACs, HDAC1 and 3 directly interacted with HIF-1α protein and then invoked HIF-1α stability and HIF-1 transactivation function under hypoxia. These results strongly indicate that the stabilization of HIF-1α protein is accelerated by interacting with HDAC1/3.

Recently, it was reported that N-terminal acetyltrans-ferase, ARD1, interacts with the ODD domain of HIF-1α and then degrades HIF-1α through its acetylation (36,44,45). In addition, Yoo *et al* (36) reported that metastasis-associated protein 1 (MTA1) promotes the deacetylation of HIF-1α by increasing the expression of HDAC1. From previous studies, it seems likely that HDAC1 and 3 are involved in the regulation of HIF-1α stability via reversible acetylation. However, since pVHL functions as a corepressor by recruiting HDAC1/3 to HIF-1α (46), further investigations would be necessary to elucidate the regulatory mechanism of HIF-1α stability by multi-protein complexes consisting of HDAC1/3 and pVHL.

Through an evaluation of the collective evidence, we conclude that HDACIs have an inhibitory effect on HIF-1α stability and HIF-1 transactivation function in human and mouse tumor cell lines. Furthermore, HDAC1 and 3 associate with the ODD domain of HIF-1α and then potentiate the transcriptional activity of HIF-1 by stabilizing HIF-1α protein. Taken together, these results are important in understanding the mechanism for HDACIs' anti-angiogenic and anti-tumorigenic activities.

Acknowledgements

References

1. Narlikar GJ, Fan H and Kingston RE: Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487, 2002.
2. Hassig CA and Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1: 300-308, 1997.
3. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
4. Hong L, Schroth GP, Matthews HR, Yau P and Bradbury EM: Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 'tail' to DNA. J Biol Chem 268: 305-314, 1993.
5. Lee DY, Hayes JJ, Pruss D and Wolfe AP: A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72: 73-84, 1993.
6. Gray SG and Ekstrom TJ: The human histone deacetylase family. Exp Cell Res 262: 75-83, 2001.
7. Gao L, Cueto MA, Asselbergs F and Atadja P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748-25755, 2002.
8. Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF, Johanson K, Sung CM, Liu R and Winkler J: Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 275: 15254-15264, 2000.
9. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS and Li X: Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21 (CIP1/WAF1) promoter. Mol Cell Biol 22: 7982-7992, 2002.
10. Wang AH, Bertos NR, Vezmar M, Pelletier N, Crosato M, Heng HH, Th'ng J, Han J and Yang XJ: HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 19: 7816-7827, 1999.
11. Bertos NR, Wang AH and Yang XJ: Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol 79: 243-252, 2001.
12. Kao HY, Downes M, Ordentlich P and Evans RM: Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev 14: 55-66, 2000.
13. Fischle W, Kiermer V, Dequiedt F and Verdin E: The emerging role of class II histone deacetylases. Biochem Cell Biol 79: 337-348, 2001.
14. Guardiola AR and Yao TP: Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277: 3350-3356, 2002.
15. Grozinger CM and Schreiber SL: Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 96: 4868-4872, 1999.
16. Grozinger CM and Schreiber SL: Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA 97: 243-252, 2000.
17. Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M and Khochbin S: Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol 10: 747-749, 2000.
18. Imai S, Armstrong CM, Kaeberlein M and Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800, 2000.
19. Guarente L: Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 14: 1021-1026, 2000.
20. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A and Yao TP: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738, 2003.
21. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458, 2002.

22. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S and Yoshida M: *In vivo* destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21: 6820-6831, 2002.

23. Kouraklis G and Theocharis S: Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anti-Cancer Agents 2: 477-484, 2002.

24. Rosato RR and Grant S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2: 30-37, 2003.

25. Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H and Naoe T: Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 13: 1316-1324, 1999.

26. Semenza GL: Regulation of mammalian O_2 homeostasis by hypoxia-inducible factor 1. Annu Rev Biol 15: 551-578, 1999.

27. Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684, 2003.

28. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O_2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.

29. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW and Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O_2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.

30. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin Jr WG: HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O_2 sensing. Science 292: 464-468, 2001.

31. Caro J: Hypoxia regulation of gene transcription. High Altitude Med Biol 2: 145-154, 2001.

32. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P and Giallong A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996.

33. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y and Fujii-Kuriyama Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273-4278, 1997.

34. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR and Kim KW: Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 277: 9-12, 2002.

35. Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.

36. Yoo YG, Kong G and Lee MO: Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1α protein by recruiting histone deacetylase 1. EMBO J 25: 1231-1241, 2006.

37. Kramer OH, Gottlicher M and Heinzel T: Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12: 294-300, 2001.

38. Marks PA, Richon VM, Breslow R and Rifkind RA: Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483, 2001.

39. Melnick A and Licht JD: Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 9: 322-332, 2002.

40. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK and Benz CC: Clinical development of histone deacetylase inhibitors as anti-cancer agents. Annu Rev Pharmacol Toxicol 45: 495-528, 2005.

41. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW and Kim KW: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.

42. Lee YM, Kim SH, Kim HS, Son MJ, Nakajima H, Kwon HJ and Kim KW: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophys Res Commun 300: 241-246, 2003.

43. Williams RJ: Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs 10: 1571-1573, 2001.

44. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ and Kim KW: Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720, 2002.

45. Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC and Kuo ML: Effect of connective tissue growth factor on hypoxia-inducible factor 1α degradation and tumor angiogenesis. J Natl Cancer Inst 98: 984-995, 2006.

46. Mahon PC, Hirota K and Semenza GL: FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686, 2001.